Lifecore Biomedical Partners with Indomo to Advance Acne Therapy

Lifecore Biomedical has announced a significant development services agreement with Indomo to support the advancement of DT-001, a corticosteroid drug candidate aimed at treating inflammatory acne lesions. This partnership will enable Lifecore to provide contract development and manufacturing organization (CDMO) support, setting the stage for the therapy’s transition into clinical trials.

Under the terms of the agreement, Lifecore will produce both engineering and clinical batches of DT-001. These batches are crucial for upcoming studies designed to prepare the product for anticipated Phase 2 clinical trials scheduled for 2026. This collaboration marks an expansion of the companies’ relationship, building on prior engagements where Lifecore was involved in formulation and process optimization for the same drug candidate.

Enhancing Treatment Accessibility

DT-001 is intended to be administered via Indomo’s investigational ClearPen intradermal self-injection device. This innovative system combines a proprietary injection device with a microneedle designed to facilitate at-home administration of the corticosteroid triamcinolone acetonide, targeting patients suffering from inflammatory acne lesions. Such advancements are particularly significant given that approximately 50 million people in the United States are affected by acne annually.

“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation,” said Paul Josephs, president and chief executive officer of Lifecore Biomedical. His statement underscores the commitment of Lifecore to enhance the therapeutic landscape for acne treatment through this collaboration.

The overarching goal of Indomo’s program is to expand access to effective treatments for inflammatory acne, providing patients with the ability to manage their condition from the comfort of their homes. As clinical development progresses, both companies are poised to make significant strides in addressing this common yet impactful skin condition.

In conclusion, the partnership between Lifecore Biomedical and Indomo represents a proactive step towards developing innovative solutions for acne treatment, reflecting the companies’ shared vision of improving patient care and treatment accessibility.